Galectin Therapeutics Management
Management criteria checks 4/4
Galectin Therapeutics' CEO ist Joel Lewis , ernannt in Sep 2020, hat eine Amtszeit von 3.25 Jahren. Die jährliche Gesamtvergütung beträgt $974.18K , bestehend aus 53.7% Gehalt und 46.3% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 1.65% der Aktien des Unternehmens, im Wert von $1.73M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 3.5 Jahre bzw. 9.3 Jahre.
Key information
Joel Lewis
Chief executive officer
US$963.6k
Total compensation
| CEO salary percentage | 59.5% |
| CEO tenure | 3.6yrs |
| CEO ownership | 1.5% |
| Management average tenure | 3.8yrs |
| Board average tenure | 8yrs |
Recent management updates
Recent updates
Galectin rises as FDA approves to begin human trial of combination immunotherapy in head and neck cancer
Oct 12Galectin Therapeutics GAAP EPS of -$0.16
Aug 15Galectin: Ability To Potentially Target Unmet Medical Need
Jul 11Galectin: Pursuing A Subset In The NASH Space
Jul 01Read This Before Buying Galectin Therapeutics, Inc. (NASDAQ:GALT) Shares
Feb 25
Is Galectin Therapeutics (NASDAQ:GALT) In A Good Position To Deliver On Growth Plans?
Jan 21How Much Of Galectin Therapeutics, Inc. (NASDAQ:GALT) Do Insiders Own?
Dec 09Galectin Therapeutics reports Q3 results
Nov 09CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | US$964k | US$574k | -US$38m |
| Sep 30 2023 | n/a | n/a | -US$45m |
| Jun 30 2023 | n/a | n/a | -US$40m |
| Mar 31 2023 | n/a | n/a | -US$40m |
| Dec 31 2022 | US$974k | US$523k | -US$39m |
| Sep 30 2022 | n/a | n/a | -US$35m |
| Jun 30 2022 | n/a | n/a | -US$35m |
| Mar 31 2022 | n/a | n/a | -US$34m |
| Dec 31 2021 | US$1m | US$500k | -US$31m |
| Sep 30 2021 | n/a | n/a | -US$31m |
| Jun 30 2021 | n/a | n/a | -US$29m |
| Mar 31 2021 | n/a | n/a | -US$26m |
| Dec 31 2020 | US$1m | US$165k | -US$24m |
| Sep 30 2020 | n/a | n/a | -US$21m |
| Jun 30 2020 | n/a | n/a | -US$18m |
| Mar 31 2020 | n/a | n/a | -US$15m |
| Dec 31 2019 | US$189k | n/a | -US$20m |
| Sep 30 2019 | n/a | n/a | -US$18m |
| Jun 30 2019 | n/a | n/a | -US$19m |
| Mar 31 2019 | n/a | n/a | -US$20m |
| Dec 31 2018 | US$55k | n/a | -US$15m |
| Sep 30 2018 | n/a | n/a | -US$14m |
| Jun 30 2018 | n/a | n/a | -US$16m |
| Mar 31 2018 | n/a | n/a | -US$17m |
| Dec 31 2017 | US$172k | n/a | -US$17m |
Vergütung im Vergleich zum Markt: JoelDie Gesamtvergütung ($USD963.65K) liegt unter dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD1.48M).
Entschädigung vs. Einkommen: JoelDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.
CEO
Joel Lewis (53 yo)
3.6yrs
Tenure
US$963,647
Compensation
Mr. Joel Lewis serves as Chief Executive Officer and President at Galectin Therapeutics, Inc since September 2, 2020 and Director since December 14, 2017. He served as the Managing Director of Shareholder...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 3.6yrs | US$963.65k | 1.45% $ 2.2m | |
| CFO, Treasurer & Corporate Secretary | 10.8yrs | US$561.42k | 0.013% $ 20.0k | |
| Chief Medical Officer | 4.1yrs | US$770.28k | 0% $ 0 | |
| General Counsel | no data | no data | no data | |
| Head of CMC & Pharmaceutical Development | 1.3yrs | no data | no data | |
| Executive Assistant & Officer Manager | no data | no data | no data |
3.8yrs
Average Tenure
56yo
Average Age
Erfahrenes Management: GALTDas Führungsteam des Unternehmens gilt als erfahren (3.5 Jahre durchschnittliche Betriebszugehörigkeit).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 6.3yrs | US$963.65k | 1.45% $ 2.2m | |
| Independent Director | 15.2yrs | US$87.24k | 0.098% $ 147.9k | |
| Independent Director | 9.6yrs | US$81.74k | 0.13% $ 200.7k | |
| Independent Chairman | 6.3yrs | US$71.74k | 16.59% $ 25.1m | |
| Independent Director | 12.5yrs | US$75.24k | 0.022% $ 33.1k | |
| Co-founder & Member of the Scientific Board | no data | US$203.69k | no data | |
| Director | 4.3yrs | US$71.74k | 0.014% $ 21.2k | |
| Member of the Scientific Board | no data | no data | no data | |
| Independent Vice Chairman of the Board | 12.9yrs | US$87.74k | 0.18% $ 279.3k | |
| Member of Clinical Advisory Board | no data | no data | no data | |
| Member of Clinical Advisory Board | no data | no data | no data | |
| Independent Director | 3.6yrs | US$86.74k | 0.049% $ 74.1k |
8.0yrs
Average Tenure
73yo
Average Age
Erfahrener Vorstand: GALTDie Vorstandsmitglieder gelten als erfahren (9.3 Jahre durchschnittliche Amtszeit).